These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38642081)

  • 1. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
    Delgado-Coka LA; Roa-Peña L; Babu S; Horowitz M; Petricoin EF; Matrisian LM; Blais EM; Marchenko N; Allard FD; Akalin A; Jiang W; Larson BK; Hendifar AE; Picozzi VJ; Choi M; Shroyer KR; Escobar-Hoyos LF
    Am J Clin Pathol; 2024 Sep; 162(3):314-326. PubMed ID: 38642081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
    Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
    Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.
    Roa-Peña L; Leiton CV; Babu S; Pan CH; Vanner EA; Akalin A; Bandovic J; Moffitt RA; Shroyer KR; Escobar-Hoyos LF
    Sci Rep; 2019 Aug; 9(1):11239. PubMed ID: 31375762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratin 17 testing in pancreatic cancer needle aspiration biopsies predicts survival.
    Roa-Peña L; Babu S; Leiton CV; Wu M; Taboada S; Akalin A; Buscaglia J; Escobar-Hoyos LF; Shroyer KR
    Cancer Cytopathol; 2021 Nov; 129(11):865-873. PubMed ID: 34076963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
    Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
    Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratin 17 modulates the immune topography of pancreatic cancer.
    Delgado-Coka L; Horowitz M; Torrente-Goncalves M; Roa-Peña L; Leiton CV; Hasan M; Babu S; Fassler D; Oentoro J; Bai JK; Petricoin EF; Matrisian LM; Blais EM; Marchenko N; Allard FD; Jiang W; Larson B; Hendifar A; Chen C; Abousamra S; Samaras D; Kurc T; Saltz J; Escobar-Hoyos LF; Shroyer KR
    J Transl Med; 2024 May; 22(1):443. PubMed ID: 38730319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcome.
    Chen Q; Chen Z; Zhang J; Cai Y; Wu S; He D; Cheng K; Gu X; Cai Y; Wang X; Li Y; Zhang M; Wu Z; Peng B
    FASEB J; 2024 Aug; 38(15):e23867. PubMed ID: 39101950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
    Rao J; Sinn M; Pelzer U; Riess H; Oettle H; Demir IE; Friess H; Jäger C; Steiger K; Muckenhuber A
    J Pathol Clin Res; 2024 May; 10(3):e12377. PubMed ID: 38750616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
    Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
    Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
    Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
    Tatarian T; Jiang W; Leiby BE; Grigoli A; Jimbo M; Dabbish N; Neoptolemos JP; Greenhalf W; Costello E; Ghaneh P; Halloran C; Palmer D; Buchler M; Yeo CJ; Winter JM; Brody JR
    Ann Surg; 2018 Feb; 267(2):364-369. PubMed ID: 27893535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
    Striefler JK; Sinn M; Pelzer U; Jühling A; Wislocka L; Bahra M; Sinn BV; Denkert C; Dörken B; Oettle H; Riess H; Bläker H; Lohneis P
    Pathol Res Pract; 2016 Aug; 212(8):726-34. PubMed ID: 27461834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.
    Shibayama T; Hayashi A; Toki M; Kitahama K; Ho YJ; Kato K; Yamada T; Kawamoto S; Kambayashi K; Ochiai K; Gondo K; Okano N; Melchor JP; Iacobuzio-Donahue CA; Sakamoto Y; Hisamatsu T; Shibahara J
    Sci Rep; 2024 Jul; 14(1):15598. PubMed ID: 38971768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
    Kato A; Naiki-Ito A; Naitoh I; Hayashi K; Nakazawa T; Shimizu S; Nishi Y; Okumura F; Inoue T; Takada H; Kondo H; Yoshida M; Takahashi S; Joh T
    Hum Pathol; 2018 Apr; 74():92-98. PubMed ID: 29339176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
    Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.